Today: 20 May 2026
Rolls-Royce Soars to Record High: What’s Fueling the Unstoppable Rally?
11 November 2025
3 mins read

Rolls‑Royce (RRL.XC / RR.L) Stock Today: Buyback Update, Insider Purchases & What to Watch Ahead of Thursday’s Trading Statement — 11 November 2025

London — 11 November 2025. Rolls‑Royce Holdings plc shares ended the session around 1,151.5p in London (‑0.82% on the day), trading between 1,144.5p and 1,168.5p and sitting within a 52‑week range of 517.2p–1,196.0p. Figures are based on LSEG/Reuters data for the LSE‑listed RR.L line.


Key takeaways (11 Nov 2025)

  • Fresh buyback print: Rolls‑Royce disclosed purchases under its £1bn share buyback, with 3,061 shares repurchased on 10 Nov at a VWAP of 1,130.0p. Since launching the programme on 27 Feb 2025, the company has now bought back 96,995,824 shares at an average 926.4389p. Treasury shares now total 32,187,898 and voting rights stand at 8,411,620,654.
  • Insider buying (PDMR): A Director/PDMR Shareholding notice shows CFO Helen McCabe and Rob Watson (President, Civil Aerospace) each purchased 17 shares on 7 Nov via the monthly employee share purchase plan, with prices recorded at £11.3295 and £11.4533 per share (plus matching shares under the plan).
  • Price context: Shares eased today after Monday’s close at 1,161.0p; attention now turns to Thursday, 13 Nov, when Rolls‑Royce issues a trading update.

What happened today

1) Transaction in own shares (11 Nov RNS)

This morning’s regulatory filing confirms Rolls‑Royce continued executing its authorised £1 billion share buyback, purchasing 3,061 ordinary shares on 10 Nov at a VWAP of 1,130.0p (highest and lowest price also 1,130.0p). Post‑transaction, the group reports 32,187,898 shares held in treasury and 8,411,620,654 voting rights outstanding. The company reiterates that the buyback, announced on 27 Feb 2025, remains in progress.

2) Director/PDMR shareholding (11 Nov RNS)

A second RNS today details modest insider purchases under the employees’ monthly share plan:

  • Helen McCabe (CFO): 13 shares at £11.3295 and 4 shares at £11.4533 (total 17), plus matching shares under the plan.
  • Rob Watson (President – Civil Aerospace): identical 13/4 split and prices, total 17 shares, plus matching shares.
    These purchases, though small in size, maintain insider alignment and came ahead of this week’s trading statement.

How the market read it

Rolls‑Royce finished the session near 1,151.5p (‑0.82%), with an intraday range of 1,144.5p to 1,168.5p. The price action reflects a holding pattern into Thursday’s update after a strong year in which the shares have regularly tested record territory.


What to watch on Thursday, 13 November 2025

  • Official timing: Rolls‑Royce is scheduled to publish a Trading Update on 13 Nov 2025 (company financial calendar).
  • Street setup: A widely read preview ahead of the release flags expectations that focus will centre on civil‑aerospace flying hours, margin progression, cash generation, and any reaffirmation of the upgraded full‑year outlook set after the strong H1. One preview cites indicative figures (e.g., revenue growth and EPS momentum) and notes the shares are up sharply year‑to‑date—underscoring high expectations into the print.
  • Backdrop: The company lifted guidance at H1, helping power the rally and underpin the current buyback and reinstated dividend policy announced earlier in the year. Watch whether management reiterates those targets and gives fresh colour on supply chain, pricing and SMR progress.

Why today’s RNS items matter

  • Buyback cadence: Even small daily prints are additive; the cumulative count (~97.0m shares) since February reduces the free float and can amplify per‑share metrics over time. Confirmation of voting rights helps institutions track disclosure thresholds and index calculations.
  • Insider alignment: Regular participation by senior leaders (CFO and divisional president) in the share plan, with matching shares, is a mild but positive governance signal heading into a key trading update.

RRL.XC vs RR.L — which ticker should you track?

Some data platforms display Rolls‑Royce under RRL.XC (an alternate vendor code/feed). The primary UK listing is RR.L on the London Stock Exchange; both identifiers refer to the same underlying equity, but UK news flow and official filings align to RR.L. For pricing and fundamentals, LSEG/Reuters lists the primary quote as RR.L.


The bottom line

  • Today (11 Nov): Routine but important news—buyback progress and insider purchases—with the share price drifting modestly lower into the 13 Nov trading update.
  • Next catalyst:Thursday’s statement is key for confirming H2 momentum after a standout first half and for any refresh on cash‑flow, capital returns and end‑market demand.

Sources

  • RNS — Transaction in own shares (11 Nov 2025): details of purchases, treasury shares, voting rights.
  • RNS — Director/PDMR Shareholding (11 Nov 2025): CFO Helen McCabe and Rob Watson plan purchases.
  • Price & trading range (11 Nov 2025): RR.L quote, day’s range, 52‑week range.
  • Financial calendar: Trading Update confirmed for 13 Nov 2025.
  • Context — guidance raised / shareholder returns: prior coverage confirming raised outlook and buyback/dividend backdrop.

Disclosure: This article is for information only and is not investment advice. Always do your own research.

Stock Market Today

  • CAVA Q1 CY2026 Earnings Beat Expectations, Shares Surge
    May 19, 2026, 6:02 PM EDT. CAVA (NYSE:CAVA) posted a strong Q1 CY2026 performance with revenue rising 32.1% year-on-year to $438.3 million, surpassing analyst estimates by 4.7%. The Mediterranean fast-casual chain reported GAAP earnings per share of $0.20, a 14% beat over consensus, and adjusted EBITDA of $61.73 million. Same-store sales increased 9.7%, while operating margin improved to 5.8% from 4.7% a year earlier. The company ended the quarter with 459 locations, up from 393. CEO Brett Schulman highlighted CAVA's resilience amid macroeconomic and geopolitical pressures. Market capitalization stands at $9.3 billion. Analysts forecast 20.5% revenue growth for the next 12 months, reflecting confidence in the brand's expansion and menu offerings despite a projected growth slowdown.

Latest articles

POET Stock Just Raised $400 Million — Why Traders Still Hit Sell

POET Stock Just Raised $400 Million — Why Traders Still Hit Sell

20 May 2026
POET Technologies shares fell 8.02% to $13.07 on Tuesday, despite closing a $400 million financing deal with MMCAP International. The company issued over 19 million shares and warrants at $21 per package, aiming to expand production capacity tenfold. POET reported a first-quarter net loss of $12.3 million on $503,389 in revenue. A new $50 million order from Lumilens could scale to $500 million over five years.
Microsoft Shares Slip Again While AI Bulls Confront Rate Jitters

Microsoft Shares Slip Again While AI Bulls Confront Rate Jitters

19 May 2026
Microsoft shares fell 1.4% to $417.42 on Tuesday as rising U.S. Treasury yields pressured large tech stocks. The Nasdaq Composite dropped 0.84%. Microsoft’s market value stood at about $3.1 trillion. The company’s India president said its largest data center in the country will open by mid-2026 amid strong demand for Azure and AI tools.
Skillz Stock Jumps 18% as Traders Eye $420 Million Papaya Verdict

Skillz Stock Jumps 18% as Traders Eye $420 Million Papaya Verdict

19 May 2026
Skillz shares rose 18.2% to $7.80 Tuesday, valuing the company near $120 million. Investors focused on a June court decision after a federal jury ordered Papaya Gaming to pay $420 million in damages for false advertising. Skillz reported a first-quarter net loss of $10.9 million on $29.1 million revenue. The court has not finalized the damages award.
Endava (DAVA) Sinks After Q1 FY26 Miss; FY26 Outlook Trimmed as Company Expands TRD U.S.A. Partnership — Nov 11, 2025
Previous Story

Endava (DAVA) Sinks After Q1 FY26 Miss; FY26 Outlook Trimmed as Company Expands TRD U.S.A. Partnership — Nov 11, 2025

Pfizer (PFE) Stock at a Crossroads: Big Dividend, Weight-Loss Gamble & 2025 Outlook
Next Story

Pfizer (PFE) Today — Nov. 11, 2025: $10B Metsera Deal Nears Vote, Oncology Game Plan Expands, Shares Rise

Go toTop